Live on XaptiqUGC NET Economics (Dec 2026) and IIT JAM Economics (EN) test series are now live on Xaptiq.View test series
IndustryTrade PolicyInternational EconomicsTrade AgreementsInvestment Treaties

India-UK CETA left investment, pharma IP and carbon tax unresolved

The India-UK Comprehensive Economic and Trade Agreement (CETA) took effect on July 15, 2026 with tariff cuts on 99% of Indian exports, but three high-friction issues — investment protection, pharmaceutical patent standards and the UK's carbon border tax — were kept out of the deal.

What happened

CETA came into force on July 15, 2026, cutting tariffs on 99% of Indian exports to the UK and loosening some mobility rules for professionals. Commerce Minister Piyush Goyal has said the deal covers only issues where both sides could agree; three unresolved gaps remain. First, CETA has no dedicated investment chapter, unlike India's earlier agreements with the European Free Trade Association (EFTA) and New Zealand. Second, UK pharmaceutical firms will not get wider access to the Indian market because India kept Section 3(d) of The Patents Act, 1970, which curbs 'evergreening' of patents on minor drug modifications. Third, the UK's Carbon Border Adjustment Mechanism (CBAM), which starts on January 1, 2027, sits outside CETA entirely and will still apply to Indian steel, aluminium and cement.

Context

India cancelled almost all its Bilateral Investment Treaties (BITs) in 2017, moving away from a regime that let a foreign investor go straight to international arbitration if a dispute arose with the Indian government. Under the current position, investors must first exhaust the Indian legal process for a set period before arbitration is available. That change of stance has stalled BIT talks with several partners, including the UK. On pharmaceuticals, the UK exports around £26 billion of medicines globally but only £127 million, or 0.5%, to India, precisely because Indian generics manufactured under Section 3(d) already meet most demand — and the UK's own National Health Service is a large buyer of those Indian generics. On CBAM, the UK's trade commissioner for South Asia has said 'we made it clear from day one that CBAM was never part of the FTA'.

Why it matters

CETA reads as a tariff-and-market-access agreement, not a full economic integration treaty. That distinction matters for exam-relevant frameworks: economic integration usually moves through free trade area, then customs union, then common market, then economic union, layering in factor mobility, investment rules and regulatory harmonisation as it deepens. CETA sits at the first rung — border-tariff liberalisation — and deliberately postpones the harder second-rung questions (investor-state dispute settlement, IP standards, cross-border carbon adjustments) that shape actual capital and technology flows. It also shows the limits of trade deals as a shield against unilateral climate policy: an FTA can cut a UK import duty on Indian steel while a separate CBAM charge is layered on for the same shipment.

Impact for India

  • Indian steel, aluminium and cement exporters get the tariff benefit today but face the UK's CBAM charge from January 1, 2027, likely offsetting part of the benefit for carbon-intensive shipments.
  • Indian generic pharmaceutical manufacturers retain their competitive position in the UK because India held Section 3(d) intact, keeping the door open to generics after the original patent expires.
  • UK pharmaceutical exporters continue to face a narrow Indian market — the UK's own numbers show only 0.5% of its £26 billion medicine exports go to India.
  • UK investors into India have no CETA-based investment protection or investor-state dispute mechanism; disputes route through Indian courts before any international arbitration.
  • Indian exporters of professional services get some easier mobility, but the deal stops well short of the deeper commitments seen in the EFTA and New Zealand agreements.

Key data

CETA entry into force: July 15, 2026
Indian exports covered by CETA tariff cuts: 99%
UK's global medicine exports: £26 billionOnly £127 million (0.5%) go to India
UK CBAM start date: January 1, 2027Applies to carbon-intensive imports such as steel, aluminium and cement
Year India cancelled almost all BITs: 2017

Concepts

CETA (Comprehensive Economic and Trade Agreement)A bilateral trade agreement covering goods, services and rules-based provisions. Depth varies deal to deal — some CETAs include full investment and government-procurement chapters, others stay closer to tariff-focused free trade areas.India-UK CETA is on the lighter end: it covers tariffs and services mobility but not investment protection, pharma IP or climate-linked border adjustments.
Bilateral Investment Treaty (BIT)A treaty between two countries granting foreign investors substantive protections (against expropriation, unfair treatment) and the right to bring disputes to international arbitration rather than the host country's courts.India cancelled almost all its BITs in 2017 to review them; the absence of a new BIT with the UK is the direct reason CETA has no investment chapter.
Section 3(d) of The Patents Act, 1970A provision in Indian patent law that bars fresh patents for minor modifications of a known drug unless the modification shows enhanced therapeutic efficacy. It curbs 'evergreening' — the practice of extending patent monopoly through incremental tweaks.India kept Section 3(d) despite UK pressure during CETA talks, preserving space for Indian generic manufacturers once the original patent expires.
Carbon Border Adjustment Mechanism (CBAM)A charge on imports of carbon-intensive goods, calibrated to approximate the carbon cost a domestic producer would face for the same emissions. Its purpose is to prevent 'carbon leakage' — production shifting to jurisdictions with looser climate policy.The UK's CBAM takes effect on January 1, 2027 and sits outside CETA; it will still apply to Indian steel, aluminium and cement even after their CETA tariffs fall.

Theory lens

Stages of economic integration (Balassa) — free trade area, customs union, common market, economic union

Stakeholders

Gains: Indian generic pharmaceutical manufacturersSection 3(d) stays intact, blocking evergreening and preserving generic entry when patents expire
Gains: Indian labour-intensive exporters to the UKTariff cuts on 99% of Indian exports to the UK take effect from July 15, 2026
Gains: UK's National Health ServiceContinued access to low-cost Indian generic medicines is preserved
Pressure point: Indian carbon-intensive exporters (steel, aluminium, cement)UK's CBAM starts January 1, 2027 and will charge a fee matching UK producers' emissions cost, outside the CETA framework
Pressure point: UK pharmaceutical exportersSection 3(d) and India's patent stance keep the effective market share at around 0.5% of UK medicine exports
Pressure point: UK investors into IndiaNo CETA investment chapter and no BIT; disputes must move through the Indian legal system before international arbitration

Practice Question — from the story

With reference to the India-U.K. Comprehensive Economic and Trade Agreement (CETA), consider the following statements:

  1. CETA came into force on July 15, 2026 and includes a dedicated investment chapter modelled on India's earlier agreements with EFTA and New Zealand.
  2. The U.K.'s Carbon Border Adjustment Mechanism (CBAM), due to come into force on January 1, 2027, was kept outside CETA and will still apply to Indian exports of steel, aluminium and cement.

Which of the statements given above is/are correct?

  1. 1 only
  2. 2 only
  3. Both 1 and 2
  4. Neither 1 nor 2
Reveal answer & explanation

Answer: 2 only

  • Statement 1: Incorrect. CETA did come into force on July 15, 2026, but the source is explicit that CETA has no dedicated investment chapter, unlike India's EFTA and New Zealand agreements which do include investment commitments.
  • Statement 2: Correct. The U.K. trade commissioner said CBAM 'was never part of the FTA'; CBAM starts on January 1, 2027 and will still charge Indian steel, aluminium and cement exporters even after CETA tariffs fall.

Therefore, the correct answer is 2 only.

Concept check — test your understanding

In pharmaceutical patent policy, 'evergreening' — the practice that India's Section 3(d) is designed to curb — refers to which of the following?

  1. Extending patent protection by transferring the patent to a subsidiary in a low-tax jurisdiction
  2. Licensing a patented drug to a foreign manufacturer under compulsory licensing provisions
  3. Issuing a patent that covers only the process of manufacturing a known drug, not the drug itself
  4. Obtaining fresh patents on minor modifications of a known drug without demonstrating enhanced therapeutic efficacy, thereby extending the monopoly beyond the original patent's term
Reveal answer & explanation

Answer: D

  • Evergreening is the strategy of stacking incremental patents (new salt, new dosage form, new combination) on top of an expiring one to keep generics out; Section 3(d) requires an enhanced-therapeutic-efficacy test for such follow-on patents in India.
  • Option A describes patent-based transfer pricing, a tax rather than patent-term strategy.
  • Option B describes compulsory licensing, a mechanism that overrides an active patent, not one that extends it.
  • Option C describes process patents — India's older process-only regime — which is a distinct patent-scope question, not a term-extension strategy.